Childhood Cancer Awareness Month: Therapies exhibit efficacy for glioma, sarcoma, lymphoma
Click Here to Manage Email Alerts
September is Childhood Cancer Awareness Month.
The campaign is intended to spotlight the types of cancer that largely affect children, draw attention to survivorship issues, and raise funds for research and family support.
In conjunction with this observance, Healio presents the following updates in pediatric oncology that may be important to your practice.
1. Survivors of childhood cancer exhibited risk for a high burden of long-term chronic health conditions — including obesity in adulthood — due in part to specific cancer treatments. Read more.
2. Researchers are evaluating a high-frequency monitoring device to detect fever among pediatric patients with cancer being monitored at home. Read more.
3. The oncolytic adenovirus DNX-2401 (DNAtrix) appeared safe and feasible among a small cohort of pediatric patients with diffuse intrinsic pontine glioma. Read more.
4. Childhood, adolescent and young adult survivors of bone and soft tissue sarcomas had an increased risk for second malignant neoplasms. Read more.
5. Genomic sequencing of tumors enabled pediatric patients with cancer who experienced relapse to receive an appropriate matched therapy that is not standard of care. Read more.
6. The addition of bortezomib (Velcade; Millennium/Takeda) to chemotherapy significantly improved survival outcomes among children and young adults with T-cell lymphoblastic lymphoma. Read more.
7. Combining brentuximab vedotin (Adcetris, Seagen) with a chemotherapy regimen as first-line therapy conferred an objective response among 88% of younger patients with newly diagnosed advanced-stage classical Hodgkin lymphoma. Read more.
8. A combination of two targeted therapies — dabrafenib (Tafinlar, Novartis) and trametinib (Mekinist, Novartis) — significantly improved outcomes compared with standard care for children with BRAF V600 mutation-positive low-grade glioma. Read more.
9. The addition of daratumumab (Darzalex, Janssen) to chemotherapy improved outcomes among younger patients with relapsed or refractory T-cell acute lymphoblastic leukemia. Read more.
10. Hispanic children with high-risk neuroblastoma had worse survival outcomes than other children with the disease despite receiving treatment on clinical trials with standardized protocols. Read more.
Collapse
Healio Coverage
Read more about
Click Here to Manage Email Alerts